Status:
COMPLETED
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Leukemia
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, pati...
Detailed Description
Objectives The primary objective is to determine the incidence of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic...
Eligibility Criteria
Inclusion
- Receiving a G-CSF after the institution practice change
- Receiving a G-CSF for one of the following indications:
- Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma
- Mobilization of hematopoietic progenitor cells
- Neutropenia prevention following autologous hematopoietic cell transplant
- Took loratadine per protocol with G-CSF administration
- Completed a survey
Exclusion
- Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain
- Taking daily NSAIDs, with the exception of aspirin, for chronic conditions
- Treatment for solid tumor cancers
- Receiving bone modifying agents for bone pain associated with metastatic disease or other chronic conditions
Key Trial Info
Start Date :
December 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT02305979
Start Date
December 1 2014
End Date
September 1 2017
Last Update
July 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States, 27157